Nasdaq:RLAY
Relay Therapeutics, Inc.
Relay Therapeutics is an innovative biopharmaceutical firm specializing in novel treatments for severe respiratory conditions like COPD and asthma.
Key Metrics
Investment Thesis
Bull Case
Investors might buy RLAY if they believe the company's pipeline for severe respiratory diseases has high potential for blockbuster status once clinical hurdles are cleared. The recent revenue growth suggests improving commercial viability, and the company still holds over $84M in cash to fund operations for several years. A successful data readout could trigger significant value re-rating given the current low valuation relative to potential upside.
Bear Case
Investors should avoid RLAY due to persistent massive net losses exceeding $276M annually, which poses a threat of insolvency without further capital raises. The high operating expenses and lack of consistent profitability indicate that the company remains in an early-stage, speculative phase with no guaranteed path to cash flow positivity. Regulatory risks and the potential for clinical trial failures could wipe out remaining equity value before any product launch.
About Relay Therapeutics, Inc.
Relay Therapeutics is a biopharmaceutical company focused on developing therapies for severe respiratory diseases such as COPD and asthma. The company operates in the US and international markets with a pipeline targeting unmet medical needs in pulmonary health. Its primary revenue streams currently consist of product sales, though significant cash flows are driven by financing activities to support R&D.
Analysis
Management Discussion
Relay Therapeutics reported a revenue increase to $15.4M in 2025 compared to $10M the prior year, indicating growing commercial traction or partnership income. However, the company continues to post substantial net losses of $-276.5M, primarily driven by high operating expenses and R&D investments totaling over $318M. Cash reserves decreased by $41.1M from 2024 to 2025, signaling ongoing cash burn that requires continued access to capital markets.
Industry Overview
The respiratory care industry is dominated by established therapies for common conditions but faces unmet needs in severe COPD and asthma. Innovation in this sector is driven by a search for new mechanisms of action to treat patients who do not respond to standard-of-care treatments. Competition is intense, with large pharmaceutical companies and biotech firms racing to bring next-generation biologics and small molecules to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.4M | $25.5M | $10.0M | $15.4M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.4M | $25.5M | $10.0M | $15.4M |
| Operating Expenses | $300.7M | $398.5M | $382.5M | $318.1M |
| Operating Income | $-299.3M | $-373.0M | $-372.5M | $-302.7M |
| G&A | $66.0M | $75.0M | $76.6M | $56.7M |
| Stock-Based Comp | $56.1M | $86.0M | $94.1M | $62.4M |
| Depreciation | $4.1M | $5.3M | $5.5M | $3.6M |
| Other OpEx | $234.7M | $323.6M | $305.9M | $261.4M |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | $8.8M | $31.0M | $34.7M | $27.0M |
| Pre-Tax Income | $-299.3M | $-373.0M | $-372.5M | $-302.7M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-299.3M | $-373.0M | $-372.5M | $-302.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-290.5M | $-342.0M | $-337.7M | $-276.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-290.5M | $-342.0M | $-337.7M | $-276.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.02B | $770.1M | $809.2M | $578.3M |
| Cash & Equivalents | $151.8M | $143.7M | $124.3M | $84.0M |
| Accounts Receivable | $306.0K | — | — | — |
| Other Current Assets | $867.4M | $626.4M | $684.9M | $494.3M |
| Long-Term Assets | $80.3M | $73.9M | $62.1M | $43.1M |
| PP&E (Net) | $11.6M | $10.9M | $5.9M | $1.7M |
| Operating Leases | $63.8M | $58.0M | $51.8M | $40.0M |
| Other LT Assets | $4.9M | $5.0M | $4.4M | $1.3M |
| Total Assets | $1.10B | $844.0M | $871.3M | $621.3M |
| Current Liabilities | $63.7M | $30.3M | $50.7M | $25.6M |
| Accounts Payable | $10.6M | $9.2M | $14.1M | $7.7M |
| Current Leases | $4.3M | $5.0M | $5.7M | $3.8M |
| Other Current Liab | $26.2M | $1.2M | $9.7M | $463.0K |
| Long-Term Liabilities | $85.8M | $61.7M | $42.8M | $28.7M |
| LT Operating Leases | $53.5M | $48.5M | $42.8M | $28.7M |
| Other LT Liab | $32.4M | $13.2M | $0 | $0 |
| Total Liabilities | $149.6M | $92.0M | $93.5M | $54.3M |
| Shareholders' Equity | $950.2M | $752.0M | $777.8M | $567.1M |
| Paid-In Capital | $2.02B | $2.15B | $2.52B | $2.58B |
| Retained Earnings | $-1.06B | $-1.40B | $-1.74B | $-2.01B |
| AOCI | $-10.4M | $-196.0K | $-991.0K | $733.0K |
| Total L&E | $1.10B | $844.0M | $871.3M | $621.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-290.5M | $-342.0M | $-337.7M | $-276.5M |
| Non-Cash Adjustments | $36.8M | $76.8M | $64.5M | $63.3M |
| Working Capital Changes | $24.2M | $-35.1M | $24.1M | $-22.3M |
| Cash from Operations | $-229.5M | $-300.3M | $-249.1M | $-235.5M |
| Capital Expenditures | $9.1M | $4.1M | $2.0M | $410.0K |
| Cash from Investing | $-188.7M | $257.6M | $-41.1M | $192.8M |
| Cash from Financing | $289.9M | $34.8M | $270.2M | $1.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-128.3M | $-7.9M | $-20.0M | $-41.1M |
| Beginning Cash | $282.7M | $154.4M | $146.4M | $126.4M |
| Ending Cash | $154.4M | $146.4M | $126.4M | $85.4M |
Frequently Asked Questions
How does Relay Therapeutics, Inc. make money?
1) Pulmonary Drug Development: The core segment focused on discovering and developing proprietary therapies for severe respiratory diseases. 2) Product Sales: Revenue generated from the commercialization of approved or late-stage pipeline products, showing a recent increase to $15.4M in 2025. 3) Strategic Partnerships: Activities related to licensing agreements or collaborations that may contribute to cash flow and asset growth.
What are the main risks for RLAY?
1) Clinical Trial Failure: High risk that ongoing or future clinical trials for their drug candidates may fail to meet efficacy or safety endpoints. 2) Regulatory Uncertainty: Potential delays or rejections by the FDA or international regulators could halt revenue generation and increase costs. 3) Cash Burn Rate: Significant net losses ($-276.5M in 2025) indicate a heavy reliance on external financing, creating liquidity risk if capital markets tighten. 4) Commercialization Challenges: Difficulty achieving market penetration for novel therapies in a crowded competitive landscape of established respiratory medications.
What is RLAY's competitive advantage?
1) Novel Mechanism of Action: Possession of unique drug candidates targeting specific inflammatory pathways in severe respiratory diseases not addressed by current therapies. 2) Experienced Management Team: A leadership group with deep expertise in pulmonology and drug development capable of navigating complex regulatory landscapes. 3) Strong Balance Sheet Positioning: Despite losses, the company maintains significant cash reserves ($84M) and paid-in capital to fund long-term R&D without immediate dilution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.